Protocol Ledger

NCT05570058 · Phase II · ACTIVE NOT RECRUITING

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT05570058 sponsored by Redx Pharma in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-08 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05570058
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05570058
Protocol FieldVerified Registry Value
NCT IdentifierNCT05570058
Consolidated Lead SponsorRedx Pharma
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2022-09-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05570058
Hospital Research SiteLocationSite Profile
Medical University of ViennaVienna, AustriaOpen Hospital Dossier ->
Hospital Universitario La PazMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario Central de AsturiasOviedo, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI